{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:25:59Z","timestamp":1790515559460,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clin Oncol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1111\/ajco.12465","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T08:22:42Z","timestamp":1459412562000},"page":"61-67","source":"Crossref","is-referenced-by-count":19,"title":["Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma"],"prefix":"10.1111","volume":"13","author":[{"given":"Sung Hee","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Gyu","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Chung-Ang University College of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Samsung Changwon Hospital; Sungkyunkwan University School of Medicine; Changwon Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Dong-A University; College of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Yi","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine; Hanyang University Hospital; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hyoung","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine; Dankook University Hospital; Cheonan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"issue":"Suppl 2","key":"10.1111\/ajco.12465-BIB0001|ajco12465-cit-0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","article-title":"Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence","volume":"16","author":"Hutson","year":"2011","journal-title":"Oncologist"},{"key":"10.1111\/ajco.12465-BIB0002|ajco12465-cit-0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon \u03b1 in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ajco.12465-BIB0003|ajco12465-cit-0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ajco.12465-BIB0004|ajco12465-cit-0004","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12465-BIB0005|ajco12465-cit-0005","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon \u03b1 in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12465-BIB0006|ajco12465-cit-0006","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to antiangiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/ajco.12465-BIB0007|ajco12465-cit-0007","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/ajco.12465-BIB0008|ajco12465-cit-0008","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/ajco.12465-BIB0009|ajco12465-cit-0009","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/ajco.12465-BIB0010|ajco12465-cit-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-11-295","article-title":"Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma","volume":"11","author":"Busch","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1111\/ajco.12465-BIB0011|ajco12465-cit-0011","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12465-BIB0012|ajco12465-cit-0012","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12465-BIB0013|ajco12465-cit-0013","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ejca.2012.02.048","article-title":"Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma","volume":"48","author":"Seidel","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1111\/ajco.12465-BIB0014|ajco12465-cit-0014","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urology.2009.12.031","article-title":"Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy","volume":"76","author":"Vickers","year":"2010","journal-title":"Urology"},{"key":"10.1111\/ajco.12465-BIB0015|ajco12465-cit-0015","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/annonc\/mdr533","article-title":"Primary anti-vaxscular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors and subsequent therapy","volume":"23","author":"Heng","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/ajco.12465-BIB0016|ajco12465-cit-0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2014.0018","article-title":"Kidney cancer, version 2.2014","volume":"12","author":"Motzer","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/ajco.12465-BIB0017|ajco12465-cit-0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-10-695","article-title":"Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib","volume":"10","author":"Gruenwald","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1111\/ajco.12465-BIB0018|ajco12465-cit-0018","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","article-title":"Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes","volume":"29","author":"Xu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12465-BIB0019|ajco12465-cit-0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/annonc\/mdr047","article-title":"A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma","volume":"23","author":"Zurita","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/ajco.12465-BIB0020|ajco12465-cit-0020","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"10.1111\/ajco.12465-BIB0021|ajco12465-cit-0021","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"10.1111\/ajco.12465-BIB0022|ajco12465-cit-0022","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/ajco.12465-BIB0023|ajco12465-cit-0023","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ajco.12465-BIB0024|ajco12465-cit-0024","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12465","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajco.12465\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T08:16:34Z","timestamp":1625300194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12465"}},"subtitle":["Intrinsic resistance to sunitinib in RCC"],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ajco.12465","archive":["Portico"],"relation":{},"ISSN":["1743-7555"],"issn-type":[{"value":"1743-7555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}